There are 449 resources available
New kids on the block: Treatments and technologies
Presenter: Sanjay Popat
Session: Advances in the lung cancer pathway (Patient advocacy session)
Resources:
Slides
Webcast
Safety considerations for ADCs
Presenter: Egbert Smit
Session: Daiichi Sankyo - Targeting rare mutations in NSCLC: A focus on HER2m
Resources:
Webcast
Real world impact of innovations in the care pathway
Presenter: Nicoline Ehrhardt
Session: Advances in the lung cancer pathway (Patient advocacy session)
Resources:
Slides
Webcast
Q&A and discussion
Session: Advances in the lung cancer pathway (Patient advocacy session)
Resources:
Webcast
Audience Q&A and closing remarks
Presenter: Egbert Smit
Session: Daiichi Sankyo - Targeting rare mutations in NSCLC: A focus on HER2m
Resources:
Webcast
7P - Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC
Presenter: Luis Paz-Ares
Session: Poster Display session
8P - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: Secondary analyses of patient-relevant endpoints from MARIPOSA-2
Presenter: Pascale Tomasini
Session: Poster Display session
9P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)
Presenter: Chee Lee
Session: Poster Display session
10P - Safety and tolerability of first-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: Data from FLAURA2
Presenter: Chee Lee
Session: Poster Display session
11P - Patritumab deruxtecan (HER3-DXd) in previously treated patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01
Presenter: Hidetoshi Hayashi
Session: Poster Display session